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The immune system is incredibly complex in its means of main-
taining health and protecting the body against foreign invasion. 
It is a network of cells, tissues, and organs that work together 
to defend the body against “invaders” known as antigens. If the 
body recognizes a cell as being “non-self”, it triggers an immune 
response against the antigen. The immune response includes 
different cells that the body stores in preparation for attack 
(Storey, Jordan, 2008). 
All immune cells begin as immature stem cells in the bone mar-
row. They respond to cytokines (which are proteins involved 
with immune system cell communication) and other signals to 
develop into B cells, T cells, and phagocytes. B cells’ main role is 
to secrete antibodies. When B-cells encounter an antigen, they 
create plasma cells for that antigen, which then secretes hun-
dreds of identical antibodies that are specific to that antigen. 
Antibodies, also known as IG- immunoglobin, are highly specific 
proteins found in body fluids that identify antigens and connect 
to them with its specific shape and mark them for destruction. 
They neutralize the antigen and prevent it from attacking a host 
cell. Phagocytic cells then destroy the antigen (Storey, Jordan, 
2008).
Another type of immune cell is called a T-cell. There are two 
different types of T cells; Helper T cells (CD4’s) contribute by 
directing immune responses, and Killer T cells (CD8’s) attack 
infected cells. The Major Histocompatibility Complex (MHC) 
are proteins on cell surfaces and code for the specific unique 
proteins that the cell contains. MHC protein bind to the sur-
faces of antigenic cells and help T-cells distinguish other cells as 
being self or nonself (Adar, et. al. 2015). 
This leads to the concept of transplantation. If foreign tissue 
is implanted in the body, the T-cells will recognize the tissue’s 
MHC as being nonself and will therefore attack it. A fetus has 
the distinction of being a tissue alloantigen in the mother’s body. 
This is because it is impossible for a mother and child to be 
genetically identical since the fetus inherits a set of genes from 
each parent so the paternal genes are going to be considered 
foreign to the maternal immune system (Mellor, Munn, 2007). 
Furthermore, if the fetus is a boy, then they are certainly genet-
ically different due to the presence of the Y chromosome in all 
males (Simpson, et. al. 1997). Consequently, one would assume 
that the maternal immune system would identify the fetus as 
being a foreign tissue and reject it. However, nature proves that 
this is not the case. Additionally, pregnant women do not seem 
to be more susceptible to infection. This proves that the ma-
ternal immune system is functioning and carrying out all other 
appropriate immune responses (Sacks, et. al. 1999). The purpose 
of this review is to explore this unusual relationship, and by sur-
veying the recent literature, gain insight into the complexities 
of the immune system and explain this seemingly paradoxical 
relationship.  The first to have raised the question of the mater-
nal-fetal immunological paradox was Peter Medawar. His initial 
1953 lecture and essay on this topic led to extensive research 
till this day. Retrospectively, scientists give him the distinction as 
the father of reproductive immunology. Upon doing pioneering 
research on skin graft rejection, Medawar wondered why a fetus 
is different than any other foreign transplant if the body clearly 
tolerizes its presence. He proposed three possible explanations; 
the mother and fetus have a physical anatomical separation, the 
antigenic immaturity of the fetus, and the immunological inert-
ness of the mother (Billington, 2003).
Methods
Research was compiled from original journal articles, accessed 
through Touro’s online library (www.tourolib.org) which has a 
subscription to the EBSCO and ProQuest databases. Key phras-
es such as maternal fetal immunology, rejection of fetus, and 
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tolerization of fetal allograft were searched to find relevant in-
formation. These were the basis for this comprehensive review 
of the topic. 
Discussion
The first to have raised the question of the maternal-fetal im-
munological paradox was Peter Medawar. His initial 1953 lec-
ture and essay on this topic led to extensive research till this 
day. Retrospectively, scientists give him the distinction as the 
father of reproductive immunology. Upon doing pioneering re-
search on skin graft rejection, Medawar wondered why a fetus 
is different than any other foreign transplant if the body clearly 
tolerizes its presence. He proposed three possible explanations; 
the mother and fetus have a physical anatomical separation, the 
antigenic immaturity of the fetus, and the immunological inert-
ness of the mother (Billington, 2003).
T cell Awareness of Fetal Presence
In response to Medawar’s first hypothesis, research was done 
to test if the maternal immune system is aware of the fetus’s 
presence. The trophoblast is a tissue layer that surrounds the 
embryonic cells. It supplies that embryo with nutrients, and its 
outer layer separates the fetal and maternal circulatory system 
throughout the entire pregnancy (Bonney, Matzinger, 1997). 
Researchers performed an experiment to discover if there are 
fetal MHC molecules at the extraembryonic tissues and if so, 
if the paternal genes are present in equal proportion to the 
maternally inherited genes. They implanted an embryo with pa-
ternal (foreign) and maternal (identical) MHC class 1 genes in a 
mouse and tracked them. On day 13 of gestation, fetal cells had 
low levels of MHC class 1 genes, yet equivocally high levels of 
both paternally and maternally derived genes were present at 
the interface of the extraembryonic and uterine tissues . Since 
the paternally derived genes are present in high numbers at the 
interface, it is unlikely that the paternal antigens are not acces-
sible to the maternal immune cells. This study proves that the 
maternal tolerance cannot be contributed to a lack of paternal 
gene expression or to a lack of contact between the mother’s 
immune system and fetal cells (Philpott, et. al. 1988).
Another study which strengthens this point was done on mice 
in which H-2K females were mated with H-2B males. For com-
parison purposes, they also mated these females to H-2K syn-
ergic mice and a third party, H-2s bearing mice. When tested 
mid-pregnancy, mice bearing H-2B conceptuses had reduced 
numbers of T cells with high expression of the clonotype and 
6-9 times more clonotype positive cells that were missing CD4 
and CD8 than the control mice. This reaction proves that the 
maternal T cells are exposed to and recognize the paternal allo-
antigen (Tafuri, et al. 1995).
They tested the mice further to determine if the T cell changes 
were still present after delivery of the fetus and found that the 
T cells were restored to the same levels as the control mice. 
However, that could just indicate that there is only tolerization 
when the paternal alloantigen is present in the body. To test this, 
after delivery, they introduced grafts of the H-2KB gene and 
the mice rejected it. They have also tried transplanting paternal 
grafts and have found that the mother’s immune system only 
accepted it if the MHC peptide complexes on the graft were 
identical to that of the fetus. After the pregnancy, however, the 
maternal immune system did reject the graft. This study proved 
that pregnancy induces a transient state of tolerance for the 
paternally derived genes of the fetus (Tafuri, et. al. 1995).
These studies indicate that Medawar’s first two hypotheses 
were wrong. The maternal tolerance is clearly not due to lack of 
exposure, and must be contributed to some mechanism which 
occurs during pregnancy that protects the fetus from rejection. 
As for his argument that the fetal antigenic cells are immature, 
we do see that fetal cells may lack high levels of MHC expres-
sion during gestation. However, he was assuming that the only 
exposure the maternal immune system has is from the fetal 
cellsf. As the above experiments proved, the trophoblast, which 
is definitely in contact with the mother’s immune cells, had 
MHC genes at high levels from the beginning of gestation. Thus, 
it cannot be that the tolerization is due to antigenic immaturity. 
Another study was done to test Medawar’s third hypothesis 
which is that the mother is in an immunological tolerant state. 
They found that the T cells in the spleen and lymph node dis-
played characteristics that were typical of functionally unre-
sponsive T cells and are not typical for antigen-experienced T 
cells (Zhou, Mellor, 1998). Researchers conclude from this data 
that maternal T cells are exposed to the paternal alloantigen’s 
and this exposure somehow induces a tolerant state. Scientists 
are now focused on trying to figure out what exactly causes this 
tolerant state. However, it is clear that the mother’s immune 
system is not suppressed, because it is responsive to all other 
antigens. Therefore, it would be inaccurate to describe the ma-
ternal immune system as being inert. 
Indoleamine 2,3-dioxygenase (IDO) Mechanism
There is a mechanism discovered by Drs. Mellor and Munn 
which is currently the most well accepted explanation for this 
immunological contradiction. They attribute this tolerance to 
the fetus shutting off the mother’s natural defenses. Their hy-
pothesis is that the embryotic cells in the placenta, known as 
syncytiotrophoblasts, produce an enzyme called indoleamine 
2,3-dioxygenase (IDO) which destroys an amino acid, trypto-
phan, that is necessary for the maternal T cells to protect the 
maternal body effectively (Munn, et. al. 1998).
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In order to test this hypothesis, an experiment was done in which 
they had four groups of female mice. Two groups (A and B) were 
mated to mice that were genetically identical to them and two 
groups were mated to mice that were genetically different (C and 
D). Levels of IDO were first assessed in all groups. IDO transcrip-
tion were present in all mice from 7.5 to 9.5 dpc (days post co-
itus). At later gestation times, such as on days 10.5 and 13.5, IDO 
was present in the placenta but not in the uterus or embryonic 
tissue. This data proves that IDO is only found in synctytiotro-
phoblasts and not in other tissue (Munn, et. al. 1998). 
1-methyl-tryptophan, a pharmacologic agent that inhibits IDO 
enzyme activity was then inserted under the skin of mice from 
groups A and C. Groups B and D were used as a control. On 
6.5 dpc, mice from all groups were carrying normal numbers of 
concepti and development was normal as well. However, from 
7.5 to 8.5 dpc, the number of concepti in mice from group C 
(mice that were mated with allogenic males and treated with 
the IDO inhibitor) decreased significantly and there was hem-
orrhaging around the concepti that were left. At 8.5 and 9.5 
dpc, all concepti showed signs of inflammation and deteriora-
tion. After 9.5 dpc, no concepti that were treated with the IDO 
inhibitor remained. To contrast, the concepti from groups A and 
B, fetuses whose parents were genetically identical, all survived 
and showed signs of normal development. This is despite group 
A having received treatment of the IDO inhibitor. Group D, 
which included the mice mated with synergetic partners, were 
not given IDO inhibitor and the pregnancy progressed normally 
and all concepti survived (Munn, et. al. 1998).
To test if a single paternal MHC class 1 difference will also lead 
to rejection, the scientists altered one gene and mated the mice. 
They found that the mice treated with IDO inhibitor all lost 
their concepti. The results of this experiments clearly indicate 
that IDO is an important factor in preventing the maternal im-
mune system from rejecting the fetus (Munn, et. al. 1998).
A closer look at this data sheds some light on the mechanism 
that is likely to be responsible for protecting the fetus from re-
jection. Data showed that fetal rejection happened very early on 
in gestation, which does not give enough time for B cells to have 
produced the appropriate antibodies. This leaves it to T cells to 
have taken the active role in rejecting the fetus. Furthermore, it 
would be impossible to attribute the fetal loss to toxic effects 
of 1-methal-tryptophan, because the synergetic mice that did 
receive the inhibitor displayed no symptoms, indicating that it 
must have been an immunological effect of the inhibitor. This 
groundbreaking study indicates that it is the fetal allograft that 
protects itself from being rejected (Munn, et. al. 1998).
Many studies have since been done to test this hypothesis. Due 
to obvious ethical considerations, it is impossible to do com-
plete experiments on humans, because of the rejection results 
that will likely occur. However, another research group tested 
for presence of the IDO enzyme in the human placenta. They 
first detected IDO at around week 14 and then levels increased 
rapidly and remained high throughout the pregnancy. When 
studying pregnancies with retarded intrauterine development, 
the IDO levels were significantly lower. This suggests that IDO 
enzyme is protecting the fetus from the maternal immune sys-
tem (Sedlmayr, et. al. 2002).
Because tryptophan is an amino acid and cannot be synthesized 
by the body, the body’s only source of it is from dietary intake. 
When placing golden hamsters on a high tryptophan diet, exper-
imenters found that there was reduced embryonic survival and 
it influenced pregnancies adversely. This seems to link tryptophan 
levels with maternal rejection of the fetus (Meier, Wilson, 1983).
Another finding which seems to give credence to Mellor and 
Munns findings is the progressive decrease of tryptophan levels in 
serum from the beginning of human pregnancy until delivery. This 
shows a distinct inverse relationship between tryptophan levels 
and successful pregnancy in humans (Schröcksnadel, et. al. 1996). 
In addition to the discovery of the role of IDO enzyme, further 
experiments indicate that there is another enzyme, Tryptophan 
2,3-dioxygenase (TDO), which also contributes to tryptophan de-
grading activities. While establishing a time course, they have found 
that on days 9.5 to 12.5, IDO enzyme was at its peak expression. 
This phase coincides with the days of placental appearance and 
growth. In this experiment, IDO levels did decrease after this small 
phase, but tolerization lasted throughout the pregnancy which can 
indicate that once tolerance is established, it lasts despite contin-
ued tryptophan activity. However, on days 5.5 to 10.5, at the early 
stages of gestation, TDO enzyme was found at high levels. It is clear 
that during this early stage, IDO enzyme is not there, as 1-me-
thal-tryptophan (an IDO inhibitor) was administered and did not 
inhibit the tryptophan degrading activities. This study suggests that 
early tryptophan inhibiting activities is due to TDO enzyme and 
during placental formation, IDO enzyme is responsible for inhibit-
ing the T cell proliferation (Suzuki, et. al. 2001).
Th-2 Bias Mechanism
Many researchers contribute the tolerization to mechanisms 
other than the IDO enzyme.  
Another mechanism that is now being researched is based on 
the link between successful pregnancy and a bias of Th2 cells. 
There are two types of helper T cells, Th1 and Th2. Th1 cell 
secretes pro inflammatory cytokines such as IFN-y and TNF-
a. Th2 cells secrete anti-inflammatory cytokines such as IL-4, 
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IL-10, and IL-13. IL-4, which is produced by Th2 inhibits the 
growth of Th1 cells. IFN-y, which is produced by Th1 inhibits the 
growth of Th2 cells. Dr. Wegmann, hypothesized that in success-
ful pregnancies, there is a strong bias of Th2 cells circulating at 
the maternal-fetal interphase. Because Th2 is anti-inflammatory, 
a significantly strong presence of Th2 cells will protect the fetus 
from th1 cells that cause inflammation and will allow fetal tol-
erization. In order to test this hypothesis, he injected pregnant 
mice with IFN-y and found that it resulted in pregnancy loss. 
This indicates that Th2 cells may promote maternal tolerance 
(Wegmann, et. al. 1993) .
Similar experiments done on both humans and mice have in-
dicated this mechanism. Several studies showed that in normal 
human pregnancies there were increased levels of Th2 cell ration 
bias and at fetal loss there was a Th1 cell ratio bias (Ng, 2002). 
Furthermore, after examining samples from pregnant women, 
they found increased expression of IL-4 mRNA and decreased 
expression of IFN-y mRNA (Tranchot-Diallo, et. al. 1997).
A study of the th1/th2 cell levels in peripheral blood of women 
showed further links. Researchers examined the blood of 
women who have a history of recurrent miscarriages which is 
assumed to have been caused by maternal rejection. Within that 
group, they had a subgroup of women who were currently in 
middle of a healthy pregnancy and a subgroup of women who 
just had a miscarriage. They found that the women in the middle 
of a normal pregnancy had a strong bias of th2 compared to the 
women who just had a miscarriage and that the women who 
just miscarried had a strong bias of th1 cells (Makhseed, et. al. 
2001). This implicates that th1/th2 cell ratio may play a signifi-
cant role in the maternal tolerization of paternal alloantigens. 
Nonconcurrent Theory
There have been suggestions that the fetal cells migrate to the 
maternal circulatory system: the lymph node, spleen, and thymus, 
where they will proliferate and then inactivate the potentially 
reactive T-cells. Several studies prove this to be the case with 
tolerized organ transplants. However, later research proved that 
it is highly unlikely that fetal cell migration can account for ma-
ternal tolerization. They found that, in fact, this scenario of fetal 
cell migration occurred in 1 out of 5 pregnant mice and at a 
level of 1-5 fetal cells per every 100,000 maternal cells. Because 
this event occurs so rarely, it doesn’t seem rational to list fetal 
cell migration as a likely mechanism that protects the fetus from 
being rejected (Bonney, Matzinger, 1997).
Clinical Implications
Recurrent Spontaneous Abortions
As the experiments on mice indicated, fetal rejection resulted 
in the death of concepti. The death was caused by the maternal 
immune system’s rejection of the placenta, which led to severe in-
flammation and hemorrhaging of the embryo, causing it to choke 
and die. This scenario can present in human pregnancy as well. 
Clinicians now wonder if the underlying explanation behind a lot of 
the miscarriages that occur is really the maternal immune system’s 
rejection of the foreign paternal alloantigen (Mellor, Munn, 2000). 
Furthermore, if it is indeed the cause of recurrent miscarriages, 
then discovering the mechanism that induces maternal tolerance 
has clinical relevance as it is essential for proper treatment. 
In order to test the IDO enzyme explanation for fetal tolerization, 
and to uncover if failure or dysfunction of this mechanism can lead 
to a miscarriage, researchers tested the cervical mucous, placental 
villi and decidua tissue. They surgically removed the tissue samples 
and mucus from women with recurrent miscarriages and divided 
the group into those that exhibited normal chromosomal group-
ings and those that did not. They compared the level of IDO en-
zyme presence to samples from women who had normal pregnan-
cies and delivery.  In samples of cervical mucous and decidua tissue 
they did not find a significant difference among levels of IDO in any 
group. However, when comparing villi from miscarried pregnan-
cies of normal chromosome analysis and abnormal chromosome 
analysis, they found that the tissue from the normal chromosome 
group had significantly higher levels of IDO enzyme than tissue of 
the abnormal chromosome group. These results suggest that IDO 
enzyme dysfunction is linked to women suffering from recurrent 
miscarriages. Further research is necessary to test if IDO enzyme 
treatment can prevent women from miscarrying by preventing the 
maternal immune rejection that likely takes place (Obayashi, et. al. 
2016).
Similarly, researchers who believe that a Th2 cell bias is respon-
sible for maternal tolerance have studied the connection be-
tween helper T cells and recurrent miscarriages. In one exper-
iment, they mated female mice who were deficient in IL-4 and 
IL-10 with male mice who were genetically different. They found 
that these mice experienced fetal loss. They treated some of 
these mice with an intraperitoneal injection of IL-10 and found 
that it protected the fetuses from resorption. (Sykes, et. al. 2012) 
Women who are suffering from recurrent spontaneous miscar-
riages are assumed to have a dysfunction in the immunological 
response to their fetus. This study implicates that by intervening 
and manipulating the levels of Th2 cells at the beginning of a 
pregnancy can protect these women from future miscarriages. 
Further research is being done on specific treatment methods. 
Preeclampsia
Preeclampsia is a pregnancy complication characterized by high 
blood pressure. The high blood pressure seems to result from 
abnormal formation of blood vessels in the placenta. ET-1 is the 
peptide which causes vasoconstriction. Studies have found that 
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increased level of ET-1 in the plasma correlated with a bias of 
th1 cells. Upon further examination, this observation can in-
dicate that if maternal tolerance mechanisms do not function 
normally, preeclampsia can occur. 
When comparing women in middle of normal pregnancies to 
women with preeclampsia, they found that the ratio of th1/th2 
was 7.6 in normal pregnancies and 11.6 in preeclampsia preg-
nancies. This shows that significant increases in levels of th1 are 
associated with preeclampsia (Kuwajima, et. al. 2001). 
The th1/th2 cytokine imbalance that is found in preeclampsia 
can be explained since th1 cell is a proinflammatory cell and the 
vasoconstriction can be a result of inflammation of the placenta 
and umbilical cord (Vargas-Rojas, et. al. 2016).
Conclusion
The mystery of why a mother does not reject her fetus, as she 
would reject any other foreign object, is the focus of much re-
search and academic debate. There is clear evidence to prove 
that the maternal immune system is in contact with the fetus 
and aware of its presence. The fetus is surely expressing pater-
nal genes that are considered foreign to the immune system. 
Furthermore, the maternal immune system seems to otherwise 
function completely as normal, indicating that there is a specific 
mechanism which must protect the fetus. One suggested mech-
anism is that the fetus secretes IDO enzyme which inhibits a 
maternal amino acid, tryptophan, which supports the T cells of 
the immune system. This forces the maternal immune system 
to tolerize the fetus. Another explanation is that tolerization 
is due to th2 bias in t cell1/2 ratio. Th2 is an anti-inflammatory 
cell and can protect the embryotic tissue from a strong immune 
response. Details of these possible mechanisms has medical rel-
evance for recurrent spontaneous abortions and preeclampsia 
because both conditions seem to be caused by immunological 
dysfunctions of the tolerization mechanism. Further research is 
being done to uncover other details of the mechanism and learn 
the entire explanation for this immunological paradox.
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